All In Biotech

Investigational drug · Phase 3

calcineurin inhibitors

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dermatitis Atopic.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

288

Any phase or sponsor naming "calcineurin inhibitors"

First trial start

2022

Aug 22, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "calcineurin inhibitors", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Dermatitis Atopic

Approved drugs for the same conditions: Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "calcineurin inhibitors" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6,355 on PubMed

Also in development for Dermatitis Atopic

  • AmlitelimabSAR445229Phase 39 trials

    Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease

  • LunsekimigSAR443765Phase 39 trials

    Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.